Sugi Predict

Sugi Predict / Compounds / SCHEMBL446203

SCHEMBL446203

SCHEMBL446203

O=C(OC(=O)C(O)CO)c1ccccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.53
▸ HPGD P15428 6/20 0.50
▸ HSD17B10 Q99714 4/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ LMNA P02545 3/20 0.49
▸ TSHR P16473 2/20 0.49
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ ADRB2 P07550 1/20 0.46
▸ ADRB1 P08588 1/20 0.46
▸ ADRB3 P13945 1/20 0.46
▸ ALDH1A1 P00352 7/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ KDM4E B2RXH2 5/20 0.42
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4372826 0.90 ALDH1A1 (0.47) TDP1HSD17B10LMNATSHRNPC1
SCHEMBL11715517 0.83 ALDH1A1 (0.51) TDP1HPGDHSD17B10ALOX15TSHR
SCHEMBL15735 0.82 ALDH1A1 (0.54) TDP1HPGDHSD17B10TSHRNPC1
SCHEMBL11335972 0.82 PTPN2 (0.45) TDP1TSHRNPC1ALDH1A1KMT2A
SCHEMBL6938590 0.80 TDP1 (0.46) TDP1HPGDHSD17B10ALOX15LMNA
SCHEMBL27540457 0.79 LMNA (0.56) TDP1HPGDHSD17B10ALOX15LMNA
SCHEMBL3908136 0.78 LMNA (0.68) TDP1HPGDHSD17B10ALOX15LMNA
SCHEMBL29525350 0.78 LMNA (0.68) TDP1HPGDHSD17B10ALOX15LMNA
SCHEMBL3390 0.77 ALDH1A1 (0.55) TDP1HPGDLMNATSHRNPC1
SCHEMBL12083435 0.77 ADRB2 (0.68) TDP1HPGDHSD17B10ALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101448482-B Glyceryl and glycol acid compounds MARY KAY INC 2013-10-09 — — CN claimed
US-7932417-B2 Glyceryl and glycol acid compounds MARY KAY INC. (US) 2011-04-26 — — US claimed
CN-101448482-A Glyceryl and glycol acid compounds MARY KAY INC (US) 2009-06-03 — — CN claimed
EP-2026753-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS Mary Kay, Inc. (US) 2009-02-25 — — EP claimed
WO-2007137128-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS MARY KAY INC. (US) 2007-11-29 — — WO claimed
US-20070269391-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS MARY KAY, INC. (US) 2007-11-22 — — US claimed
US-20240099948-A1 Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents COLABS INT'L CORP. (US) 2024-03-28 — — US disclosed
US-11839674-B2 Compositions comprising silicon dioxide-based particles including one or more agents CoLabs International Corporation (US) 2023-12-12 — — US disclosed
EP-4262712-A1 ANTI-INFLAMMATORY COMPOSITIONS The Procter & Gamble Company (US) 2023-10-25 — — EP disclosed
US-11752086-B2 Topical formulations and methods MYOCEPT INC. (US) 2023-09-12 — — US disclosed
US-11724134-B2 Compositions containing a cellulose derived capsule with a sunscreen active agent CoLabs International Corporation (US) 2023-08-15 — — US disclosed
US-11725096-B2 Zinc oxide complexes MARY KAY INC. (US) 2023-08-15 — — US disclosed
CN-116568273-A Anti-inflammatory compositions 宝洁公司 2023-08-08 — — CN disclosed
WO-2003053369-A1 ALLANTOIN-CONTAINING PREPARATIONS FOR ADMINISTRATION AS GELS AND AEROSOLS ALWYN COMPANY, INC. (US) 2003-07-03 — — WO disclosed
WO-2003041688-A1 METHODS FOR TREATMENT OF INFLAMMATORY DISEASES ALWYN COMPANY, INC. (US) 2003-05-22 — — WO disclosed
WO-2003041651-A2 ALLATOIN-CONTAINING SKIN CREAM ALWYN COMPANY, INC. (US) 2003-05-22 — — WO disclosed
US-20020054895-A1 And at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; skin protectants ALWYN COMPANY, INC. 2002-05-09 — — US disclosed
US-20020055531-A1 Methods for treatment of inflammatory diseases SWEEN, MAURICE ALWYN 2002-05-09 — — US disclosed
US-6376557-B1 TRANSDERMAL SUPPLYING ZAVERI CHANDA BHUWALKA (US) 2002-04-23 — — US disclosed
WO-2001068107-A1 HAIR RESTORATION FORMULATION ZAVERI CHANDA BHUWALKA (US) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070269391-A1 GLYCERYL AND GLYCOL ACID COMPOUNDS GLA, GK, UNG TDP1 892/4885HPGD 62/4885HSD17B10 1161/4885
US-11724134-B2 Compositions containing a cellulose derived capsule with a sunscreen active agent CUTA, ACMSD, TYR TDP1 3476/4885HPGD 2156/4885HSD17B10 1495/4885
US-11725096-B2 Zinc oxide complexes SOD1, SOD3, SLC30A6 TDP1 4433/4885HPGD 312/4885HSD17B10 1249/4885
US-11752086-B2 Topical formulations and methods KRT18, ANXA3, VIP TDP1 1505/4885HPGD 1900/4885HSD17B10 2793/4885
US-20240099948-A1 Compositions Comprising Silicon Dioxide-Based Particles Including One or More Agents MSN, LIPE, CUTA TDP1 4753/4885HPGD 4237/4885HSD17B10 3508/4885
US-11839674-B2 Compositions comprising silicon dioxide-based particles including one or more agents MSN, LIPE, CUTA TDP1 4735/4885HPGD 4272/4885HSD17B10 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.